Global Hypoactive Sexual Desire Disorder Treatment Market, Treatment Type (Therapy, Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Hypoactive Sexual Desire Disorder Treatment Market Analysis and Size
Hypoactive sexual desire disorder (HSDD) is presently on the rise in adult women population and is characterized by low self-confidence and less connection with their partners. Furthermore, conditions such as renal failure, liver disorder, hormonal imbalance, diabetes, substance addiction, alcoholism and others cause hypoactive sexual desire disorder. The increasing working women population along with their hectic work schedules, often result in low libido conditions, thereby expanding the demand for HSDD treatment.
Data Bridge Market Research analyses a growth rate in the hypoactive sexual desire disorder treatment market in the forecast period 2023-2030. The expected CAGR of hypoactive sexual desire disorder treatment market is tend to be around 4% in the mentioned forecast period. The market was valued at USD 139.7 million in 2022, and it would grow upto USD 191.2 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hypoactive Sexual Desire Disorder Treatment Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Treatment Type (Therapy, Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Sprout Pharmaceuticals, Inc. (U.S.), Covis Pharma GmbH (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Amneal Pharmaceuticals LLC. (U.S.), Zydus Group (India), Sun Pharmaceutical Industries Ltd (India), Abbvie,Inc (U.S.), EndoCeutics, Inc. (Canada), S1 BIOPHARMA INC. (U.S.) |
|
Market Opportunities |
|
Market Definition
Hypoactive sexual desire disorder is the most common type of sexual dysfunction that majorly occurs in the adult females. It is the type of condition in which there is lack of sex interest for a stretch of six months and more because of menopause, hormonal changes and the adoption of bad habits. Many patients suffering from this disorder may show the symptoms of lack of confidence, stressed, alcohol use and other behavioural changes.
Hypoactive Sexual Desire Disorder Treatment Market Dynamics
Drivers
- Increasing Awareness of Healthcare Infrastructure
A significant factor inducing the growth rate of hypoactive sexual desire disorder treatment market is the increasing healthcare expenditure, which helps improve its infrastructure. Furthermore, several government organizations aim to improve the healthcare infrastructure by growing the funding, that will further influence the market dynamics.
- Growing Level of Stress
Many people are stressed these days with many factors such as confront in the workplace, improper work-life balance, anxiety, depression that can lower the sex drive. Stress and tension at the workfront leads to a bad impact on our personal lives and can thus lead to this disorder, Thus, this instigates the demand for the treatment methods.
Opportunities
- Increasing Demand of Advanced Therapies
There are several therapies that are developed to help cure this disorder patients. Psychotherapy is recommended for patients who positively respond to counselling sessions with a sex therapist. Pharmacotherapy consists of buspirone and bupropion off-label treatment for HSDD in women suffering from low libido associated with anxiety and depression. Furthermore, testosterone transdermal patches are an off-label treatment in premenopausal and postmenopausal women with HSDD. Due to its multifunctional serotonin agonist, the US FDA approved Flibanserin for treating this condition in premenopausal women.
Restraints/Challenges
- Risk of Side-Effects
The diverse side-effects associated with hypoactive sexual desire disorder treatment could restrict the growth of the market over a forecast period. Complications such as anxiety, headache disorder, lower back pain, and irritation are prominent with the use of hypoactive sexual desire disorder treatment.
- High Cost of Treatment
There are numerous treatment processes that involves a huge cost. This type of disorder also involves counselling sessions, which demands monthly visits that cost high. Numerous hormonal therapies that are somewhat necessary for fast recovery but get unaffordable to many patients because of its high cost are impeding the market's growth.
This hypoactive sexual desire disorder treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hypoactive sexual desire disorder treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Hypoactive Sexual Desire Disorder Treatment Market Scope
The hypoactive sexual desire disorder treatment market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Therapy
- Buspirone
- Bupropion
- Testosterone
- Flibanserin
- Bremelanotide
- Cognitive Behavior Therapy
- Drugs
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Hypoactive Sexual Desire Disorder Treatment Market Regional Analysis/Insights
The hypoactive sexual desire disorder treatment market is analyzed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the hypoactive sexual desire disorder treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for hypoactive sexual desire disorder treatment market throughout the forecasted period due to increased demand of hypoactive sexual desire disorder treatment for treating libido and hypoactive sexual disorders.
North America dominates the market due to constantly increasing population resulting growing incidence of stress in working females and males.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hypoactive Sexual Desire Disorder Treatment Market Share Analysis
The hypoactive sexual desire disorder treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hypoactive sexual desire disorder treatment market.
Key players operating in the hypoactive sexual desire disorder treatment market include:
- Sprout Pharmaceuticals, Inc. (U.S.)
- Covis Pharma GmbH (U.S.)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Amneal Pharmaceuticals LLC. (U.S.)
- Zydus Group (India)
- Sun Pharmaceutical Industries Ltd (India)
- Abbvie,Inc (U.S.)
- EndoCeutics, Inc. (Canada)
- S1 BIOPHARMA INC. (U.S.)
SKU-
